Literature DB >> 33577559

Quantifying the gender gap in the HIV care cascade in southern Mozambique: We are missing the men.

Elisa Lopez-Varela1,2, Orvalho Augusto1,3, Laura Fuente-Soro1,2, Charfudin Sacoor1, Ariel Nhacolo1, Isabelle Casavant4, Esmeralda Karajeanes5, Paula Vaz5, Denise Naniche1,2.   

Abstract

BACKGROUND: HIV-infected men have higher rates of delayed diagnosis, reduced antiretroviral treatment (ART) retention and mortality than women. We aimed to assess, by gender, the first two UNAIDS 90 targets in rural southern Mozambique.
METHODS: This analysis was embedded in a larger prospective cohort enrolling individuals with new HIV diagnosis between May 2014-June 2015 from clinic and home-based testing (HBT). We assessed gender differences between steps of the HIV-cascade. Adjusted HIV-community prevalence was estimated using multiple imputation (MI).
RESULTS: Among 11,773 adults randomized in HBT (7084 female and 4689 male), the response rate before HIV testing was 48.7% among eligible men and 62.0% among women (p<0.001). MI did not significantly modify all-age HIV-prevalence for men but did decrease prevalence estimates in women from 36.4%to 33.0%. Estimated proportion of HIV-infected individuals aware of their status was 75.9% for men and 88.9% for women. In individuals <25 years, we observed up to 22.2% disparity in awareness of serostatus between genders. Among individuals eligible for ART, similar proportions of men and women initiated treatment (81.2% and 85.9%, respectively). Fourfold more men than womenwere in WHO stage III/IV AIDS at first clinical visit. Once on ART, men had a twofold higher 18-month loss to follow-up rate than women.
CONCLUSION: The contribution of missing HIV-serostatus data differentially impacted indicators of HIV prevalence and of achievement of UNAIDS targets by age and gender and men were missing long before the second 90. Increased efforts to characterize missing men and their needs will and their needs will allow us to urgently address the barriers to men accessing care and ensure men are not left behind in the UNAIDS 90-90-90 targets achievement.

Entities:  

Year:  2021        PMID: 33577559      PMCID: PMC7880488          DOI: 10.1371/journal.pone.0245461

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  30 in total

1.  Effect of facility-based HIV self-testing on uptake of testing among outpatients in Malawi: a cluster-randomised trial.

Authors:  Kathryn Dovel; Frackson Shaba; O Agatha Offorjebe; Kelvin Balakasi; Mike Nyirenda; Khumbo Phiri; Sundeep K Gupta; Vincent Wong; Chi-Hong Tseng; Brooke E Nichols; Refiloe Cele; Eric Lungu; Tobias Masina; Thomas J Coates; Risa M Hoffman
Journal:  Lancet Glob Health       Date:  2020-02       Impact factor: 26.763

2.  Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries.

Authors:  Maria Lahuerta; Yingfeng Wu; Susie Hoffman; Batya Elul; Sarah Gorrell Kulkarni; Robert H Remien; Harriet Nuwagaba-Biribonwoha; Wafaa El-Sadr; Denis Nash
Journal:  Clin Infect Dis       Date:  2013-11-05       Impact factor: 9.079

3.  High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study.

Authors:  Till Bärnighausen; Frank Tanser; Zanomsa Gqwede; Clifford Mbizana; Kobus Herbst; Marie-Louise Newell
Journal:  AIDS       Date:  2008-01-02       Impact factor: 4.177

4.  Loss to care and death before antiretroviral therapy in Durban, South Africa.

Authors:  Ingrid V Bassett; Bingxia Wang; Senica Chetty; Matilda Mazibuko; Benjamin Bearnot; Janet Giddy; Zhigang Lu; Elena Losina; Rochelle P Walensky; Kenneth A Freedberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

Review 5.  Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan Africa.

Authors:  Monisha Sharma; Roger Ying; Gillian Tarr; Ruanne Barnabas
Journal:  Nature       Date:  2015-12-03       Impact factor: 49.962

6.  Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America.

Authors:  Benjamin H Chi; Constantin T Yiannoutsos; Andrew O Westfall; Jamie E Newman; Jialun Zhou; Carina Cesar; Martin W G Brinkhof; Albert Mwango; Eric Balestre; Gabriela Carriquiry; Thira Sirisanthana; Henri Mukumbi; Jeffrey N Martin; Anna Grimsrud; Melanie Bacon; Rodolphe Thiebaut
Journal:  PLoS Med       Date:  2011-10-25       Impact factor: 11.069

7.  Mortality trends in the era of antiretroviral therapy: evidence from the Network for Analysing Longitudinal Population based HIV/AIDS data on Africa (ALPHA).

Authors:  Georges Reniers; Emma Slaymaker; Jessica Nakiyingi-Miiro; Constance Nyamukapa; Amelia Catharine Crampin; Kobus Herbst; Mark Urassa; Fred Otieno; Simon Gregson; Maquins Sewe; Denna Michael; Tom Lutalo; Victoria Hosegood; Ivan Kasamba; Alison Price; Dorean Nabukalu; Estelle Mclean; Basia Zaba
Journal:  AIDS       Date:  2014-11       Impact factor: 4.177

8.  Shifting the narrative: from "the missing men" to "we are missing the men".

Authors:  Anna Grimsrud; Wole Ameyan; James Ayieko; Tanya Shewchuk
Journal:  J Int AIDS Soc       Date:  2020-06       Impact factor: 5.396

9.  Continuum of HIV Care in Rural Mozambique: The Implications of HIV Testing Modality on Linkage and Retention.

Authors:  Elisa Lopez-Varela; Laura Fuente-Soro; Orvalho J Augusto; Charfudin Sacoor; Ariel Nhacolo; Esmeralda Karajeanes; Paula Vaz; Denise Naniche
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.731

10.  Impact of HIV Self-Test Distribution to Male Partners of ANC Clients: Results of a Randomized Controlled Trial in Kenya.

Authors:  Anthony Gichangi; Jonesmus Wambua; Stephen Mutwiwa; Rosemary Njogu; Eva Bazant; Joyce Wamicwe; Rose Wafula; Caroline J Vrana; Danielle R Stevens; Mildred Mudany; Jeffrey E Korte
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.